A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma

Trial Profile

A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Acronyms RACE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 14 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 14 Jan 2014 According to ClinicalTrials.gov record (NCT00761722) planned end date changed from 1 Jan 2014 to 1 Jun 2014.
    • 05 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top